WO2012018704A1 - Utilisation de tériflunomide dans le traitement de la sclérose en plaques - Google Patents

Utilisation de tériflunomide dans le traitement de la sclérose en plaques Download PDF

Info

Publication number
WO2012018704A1
WO2012018704A1 PCT/US2011/046076 US2011046076W WO2012018704A1 WO 2012018704 A1 WO2012018704 A1 WO 2012018704A1 US 2011046076 W US2011046076 W US 2011046076W WO 2012018704 A1 WO2012018704 A1 WO 2012018704A1
Authority
WO
WIPO (PCT)
Prior art keywords
teriflunomide
treatment
patient
acceptable salt
pharmaceutically acceptable
Prior art date
Application number
PCT/US2011/046076
Other languages
English (en)
Inventor
Ross Rocklin
Original Assignee
Sanofi-Aventis U.S. Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis U.S. Llc filed Critical Sanofi-Aventis U.S. Llc
Priority to EP11746365.3A priority Critical patent/EP2600861A1/fr
Publication of WO2012018704A1 publication Critical patent/WO2012018704A1/fr
Priority to US13/755,825 priority patent/US20130197080A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l'utilisation du tériflunomide dans le traitement de la sclérose en plaques (SP) et la gestion des risques associés à l'utilisation du tériflunomide.
PCT/US2011/046076 2010-08-02 2011-08-01 Utilisation de tériflunomide dans le traitement de la sclérose en plaques WO2012018704A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11746365.3A EP2600861A1 (fr) 2010-08-02 2011-08-01 Utilisation de tériflunomide dans le traitement de la sclérose en plaques
US13/755,825 US20130197080A1 (en) 2010-08-02 2013-01-31 Use of teriflunomide for treating multiple sclerosis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US36977910P 2010-08-02 2010-08-02
US36978010P 2010-08-02 2010-08-02
US61/369,780 2010-08-02
US61/369,779 2010-08-02
US38937510P 2010-10-04 2010-10-04
US61/389,375 2010-10-04
US201061424717P 2010-12-20 2010-12-20
US61/424,717 2010-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/755,825 Continuation US20130197080A1 (en) 2010-08-02 2013-01-31 Use of teriflunomide for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
WO2012018704A1 true WO2012018704A1 (fr) 2012-02-09

Family

ID=45559773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046076 WO2012018704A1 (fr) 2010-08-02 2011-08-01 Utilisation de tériflunomide dans le traitement de la sclérose en plaques

Country Status (4)

Country Link
EP (1) EP2600861A1 (fr)
AR (1) AR082436A1 (fr)
UY (1) UY33542A (fr)
WO (1) WO2012018704A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762135A1 (fr) * 2013-02-04 2014-08-06 Sanofi Procédés permettant de réduire le risque d'une interaction de la rosuvastatine et du tériflunomide indésirable chez des patients atteints de sclérose en plaques
WO2021204994A1 (fr) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab pour traiter la sclérose en plaques tout en maintenant l'igg sérique
US11723896B2 (en) 2017-03-14 2023-08-15 Actelion Pharmaceuticals Ltd Pharmaceutical combination comprising ponesimod

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679709A (en) 1985-09-27 1997-10-21 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases
US6794410B2 (en) 2001-04-05 2004-09-21 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679709A (en) 1985-09-27 1997-10-21 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases
US6794410B2 (en) 2001-04-05 2004-09-21 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS GOV: "Study of Teriflunomide in reducing the Frequency of relapses and Accumulation of Disability in Patients with Multiple Scelerosis (TEMSO)", INTERNET CITATION, 23 August 2005 (2005-08-23), pages 1 - 4, XP002648177, Retrieved from the Internet <URL:http://clinicaltrials.gov/ct2/show/NCT00134563> [retrieved on 20110706] *
O'CONNOR P W ET AL: "A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 66, no. 6, 28 March 2006 (2006-03-28), pages 894 - 900, XP002556504, ISSN: 0028-3878, DOI: 10.1212/01.WNL.0000203121.04509.31 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762135A1 (fr) * 2013-02-04 2014-08-06 Sanofi Procédés permettant de réduire le risque d'une interaction de la rosuvastatine et du tériflunomide indésirable chez des patients atteints de sclérose en plaques
US11723896B2 (en) 2017-03-14 2023-08-15 Actelion Pharmaceuticals Ltd Pharmaceutical combination comprising ponesimod
WO2021204994A1 (fr) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab pour traiter la sclérose en plaques tout en maintenant l'igg sérique

Also Published As

Publication number Publication date
EP2600861A1 (fr) 2013-06-12
UY33542A (es) 2012-02-29
AR082436A1 (es) 2012-12-05

Similar Documents

Publication Publication Date Title
Pearlstein et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation
Bresnihan et al. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis
EP2648732A1 (fr) Utilisation de laquinimod pour la réduction de la fatigue, l&#39;amélioration de l&#39;état fonctionnel, et l&#39;amélioration de la qualité de vie chez des patients atteints de sclérose en plaques
CN104284663A (zh) 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
JP2021530481A (ja) 肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
CN110753545A (zh) 用于前列腺癌的联合疗法
Moberly et al. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients
US9662322B2 (en) Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
US20130197080A1 (en) Use of teriflunomide for treating multiple sclerosis
EP2600861A1 (fr) Utilisation de tériflunomide dans le traitement de la sclérose en plaques
Wheatley et al. Liver regeneration in children after major hepatectomy for malignancy—evaluation using a computer-aided technique of volume measurement
Debouverie et al. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment
PAPAPETROPOULOS et al. Polymyositis and pregnancy: report of a case with three pregnancies
Marie et al. Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with ß-blockers
Conaghan et al. Disease-modifying antirheumatic drugs
US20230144895A1 (en) Methods Of Treating Multiple Sclerosis
TW201212911A (en) Use of teriflunomide for treating Multiple Sclerosis
Suzuki et al. Pulmonary arterial hypertension in an 80-year-old man with long-term use of cyclophosphamide
EP4003338A1 (fr) Méthodes de traitement de la sclérose en plaques
Etta et al. Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
Subedi et al. Visual outcome of standard treatment of sarcoid uveitis at a tertiary eye center in Nepal
Scherz Ponesimod/ACT-128800
Atkins et al. Macrophage migration inhibitory factor (MIF)--potential perspectives for immune-intervention in renal disease.
Plimack et al. From Sledgehammer to Selective: Transforming Cytotoxic Potency Through Targeted Treatments for Advanced or Metastatic Urothelial Cancer
Yates et al. SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed rheumatoid arthritis (RA)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11746365

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011746365

Country of ref document: EP